Given the association between antiphospholipid antibodies, endothelial dysfunction, and intimal hyperplasia, the use of sirolimus-eluting stents or balloons targeting the mTOR pathway may offer a promising strategy for aPL+ patients. Here, MTOR is linked to endothelial dysfunction.